{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:24:25Z","timestamp":1792002265361,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004319","name":"Shin Kong Wu Ho-Su Memorial Hospital","doi-asserted-by":"publisher","award":["2025SKHADR015"],"award-info":[{"award-number":["2025SKHADR015"]}],"id":[{"id":"10.13039\/501100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jaut.2025.103453","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T11:57:56Z","timestamp":1750507076000},"page":"103453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Association between autoimmune diseases and glucagon-like peptide-1 receptor agonists: A real-world evidence study"],"prefix":"10.1016","volume":"155","author":[{"given":"Yun-Jui","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mon-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Hsiang","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-4689","authenticated-orcid":false,"given":"Ming-Hsien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2025.103453_bib1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ndt\/gfu405","article-title":"Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease","volume":"31","author":"Karalliedde","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jaut.2025.103453_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2025.103453_bib3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40261-024-01354-2","article-title":"Real-world effectiveness of once-weekly glucagon-like Peptide-1 receptor agonists (OW GLP-1RAs) in comparison with dipeptidyl Peptidase-4 inhibitors (DPP-4is) for glycemic control and weight outcomes in type 2 diabetes mellitus (RELATE)","volume":"44","author":"Tan","year":"2024","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jaut.2025.103453_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278685","article-title":"Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: a multivariate meta-analysis","volume":"18","author":"Yeh","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2025.103453_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100502","article-title":"Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection","volume":"14","author":"Michos","year":"2023","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jaut.2025.103453_bib6","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jaut.2025.103453_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103453_bib8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/jdi.14361","article-title":"Enhanced renoprotective effects of combined glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: real-World evidence","volume":"16","author":"Jhu","year":"2025","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jaut.2025.103453_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.462","article-title":"Glucagon-like peptide agonists: a prospective review","volume":"7","author":"Mariam","year":"2024","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.jaut.2025.103453_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejim.2024.07.002","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors combination therapy versus monotherapy and major adverse cardiovascular events: do the benefits add up?","volume":"130","author":"Karakasis","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.jaut.2025.103453_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jaut.2025.103453_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000356747","article-title":"Autoimmune aspects of type 2 diabetes mellitus - a mini-review","volume":"60","author":"Itariu","year":"2014","journal-title":"Gerontology"},{"key":"10.1016\/j.jaut.2025.103453_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.997578","article-title":"GLP-1 receptor agonist as a modulator of innate immunity","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103453_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jaut.2025.103453_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3094642","article-title":"Anti\u2010inflammatory effects of GLP\u20101\u2010based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.jaut.2025.103453_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA open"},{"key":"10.1016\/j.jaut.2025.103453_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50050","article-title":"Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease","volume":"7","author":"Pan","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jaut.2025.103453_bib18","article-title":"Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks","volume":"53","author":"Wang","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jaut.2025.103453_bib19","first-page":"565","article-title":"Interpreting the declaration of helsinki (2008): must, should and different kinds of obligation","volume":"29","author":"Schmidt","year":"2010","journal-title":"Med & L"},{"key":"10.1016\/j.jaut.2025.103453_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/ijcp.12361","article-title":"GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?","volume":"68","author":"Brunton","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jaut.2025.103453_bib21","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical practice research datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.jaut.2025.103453_bib22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.arthro.2021.06.037","article-title":"Best practice guidelines for propensity score methods in medical research: consideration on theory, implementation, and reporting. A review","volume":"38","author":"Chen","year":"2022","journal-title":"Arthroscopy"},{"key":"10.1016\/j.jaut.2025.103453_bib23","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1111\/jdv.18975","article-title":"Dipeptidyl peptidase-4 inhibitors increase the risk of bullous pemphigoid in older patients with diabetes: a retrospective analysis using the Korean national health insurance database","volume":"37","author":"Kang","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jaut.2025.103453_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108546","article-title":"Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: a population-based cohort study","volume":"171","author":"Wu","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.jaut.2025.103453_bib25","article-title":"Balance diagnostics after propensity score matching","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.jaut.2025.103453_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.jaut.2025.103453_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.jaut.2025.103453_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-Based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jaut.2025.103453_bib29","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.4239\/wjd.v12.i9.1426","article-title":"Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: current evidence","volume":"12","author":"Roy","year":"2021","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.jaut.2025.103453_bib30","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12026-018-9005-8","article-title":"Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jaut.2025.103453_bib31","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00592-020-01533-5","article-title":"Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study","volume":"57","author":"Chen","year":"2020","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.jaut.2025.103453_bib32","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1111\/bcp.13955","article-title":"Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: a nationwide population-based cohort study","volume":"85","author":"Seong","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jaut.2025.103453_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20071584","article-title":"Dulaglutide modulates the development of tissue-infiltrating Th1\/Th17 cells and the pathogenicity of encephalitogenic Th1 cells in the central nervous system","volume":"20","author":"Chiou","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2025.103453_bib34","article-title":"Gut microbial signatures for glycemic responses of GLP-1 receptor agonists in type 2 diabetic patients: a pilot study","volume":"12","author":"Tsai","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.jaut.2025.103453_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-52103-x","article-title":"Metabolic and gut microbiome changes following GLP-1 or dual GLP-1\/GLP-2 receptor agonist treatment in diet-induced obese mice","volume":"9","author":"Madsen","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2025.103453_bib36","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/bies.201600008","article-title":"The gut-skin axis in health and disease: a paradigm with therapeutic implications","volume":"38","author":"O'Neill","year":"2016","journal-title":"Bioessays"},{"key":"10.1016\/j.jaut.2025.103453_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9020353","article-title":"Gut-skin axis: current knowledge of the interrelationship between microbial dysbiosis and skin conditions","volume":"9","author":"De Pessemier","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.jaut.2025.103453_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102649","article-title":"Hashimoto's thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation","volume":"19","author":"Ralli","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2025.103453_bib39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13098-020-00616-1","article-title":"Adult-onset autoimmune diabetes: comparative analysis of classical and latent presentation","volume":"12","author":"Fadiga","year":"2020","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.jaut.2025.103453_bib40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1210\/er.2018-00163","article-title":"Thyroid dysfunction and diabetes mellitus: two closely associated disorders","volume":"40","author":"Biondi","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jaut.2025.103453_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.927859","article-title":"Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.jaut.2025.103453_bib42","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/j.dsx.2019.07.020","article-title":"Thyroid dysfunction prevalence and relation to glycemic control in patients with type 2 diabetes mellitus","volume":"13","author":"Elgazar","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.jaut.2025.103453_bib43","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1007\/s11695-024-07486-w","article-title":"Role of GLP1-RA in optimizing weight loss post-bariatric surgery: a systematic review and meta-analysis","volume":"34","author":"Pereira","year":"2024","journal-title":"Obes. Surg."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125000988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125000988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:19:03Z","timestamp":1777580343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841125000988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":43,"alternative-id":["S0896841125000988"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103453","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between autoimmune diseases and glucagon-like peptide-1 receptor agonists: A real-world evidence study","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103453"}}